Zacks Investment Research on MSN
BMRN beats on Q4 earnings, to withdraw Roctavian from market
BioMarin Pharmaceutical BMRN reported fourth-quarter 2025 adjusted earnings per share of 46 cents, beating the Zacks ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results